Related Experiment Video
Updated: Jun 1, 2026
09:21
Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors
Published on: January 29, 2019
Vector characterization methods for quality control testing of recombinant adeno-associated viruses.
J Fraser Wright1, Olga Zelenaia
1Clinical Vector Core, Center for Cellular and Molecular Therapeutics, The Childrens Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, PA, USA. wrightf@email.chop.edu
Methods in Molecular Biology (Clifton, N.J.)
|May 19, 2011
Summary
Establishing quality control (QC) test methods is crucial for advancing adeno-associated virus (AAV) gene therapies. This work details QC assays to assess the safety, potency, and purity of clinical-grade AAV vectors for early-phase studies.
Area of Science:
- Biotechnology
- Molecular Biology
- Gene Therapy
Background:
- Adeno-associated virus (AAV)-based vectors are promising for human gene therapy.
- Translating AAV research into clinical applications requires robust quality control (QC).
Purpose of the Study:
- To provide an overview of QC characterization methods for clinical-grade AAV vectors.
- To detail selected assays for assessing AAV vector safety, potency, and purity.
Main Methods:
- Review of established and emerging QC assays for AAV vectors.
- Detailed descriptions of specific assays relevant to early-phase clinical studies.
Main Results:
- Identification of key QC methods for characterizing clinical-grade AAV vectors.
- Focus on assays evaluating safety, potency, and purity.
Conclusions:
- Standardized QC testing is essential for the clinical development of AAV gene therapies.
- Appropriate characterization methods ensure the quality and reliability of AAV vectors for therapeutic use.
